Patents by Inventor Honglin Li

Honglin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUND FOR INHIBITING MUTANT EGFR AND USE THEREOF
    Publication number: 20230321103
    Abstract: Provided is the use of a series of pteridinones and/or a pharmaceutically acceptable salt and a prodrug thereof as a non-canonical EGFR mutant inhibitor. Specifically, the present invention relates to the use of a series of compounds as represented by formula I and a pharmaceutical composition containing the series of compounds as represented by formula I in the preparation of a drug for treating a disease containing EGFR 20insX mutation, EGFR G719X mutation and ERBB2 mutation.
    Type: Application
    Filed: September 1, 2021
    Publication date: October 12, 2023
    Inventors: Honglin LI, Zhenjiang ZHAO, Yanyan DIAO, Zhuo CHEN
  • ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF
    Publication number: 20230190713
    Abstract: An application of a novel thiazole derivative in the treatment of an RNA virus infection and the preparation of a drug for treating an RNA virus infection. Specifically, the present invention relates to a use of a compound represented by the following formula I and a pharmaceutical composition containing a compound represented by the following formula I in treating an RNA virus infection and preparing a drug for treating a coronavirus infection.
    Type: Application
    Filed: March 2, 2021
    Publication date: June 22, 2023
    Inventors: Honglin LI, Ke XU, Shiliang LI, Lili ZHU, Zhenjiang ZHAO
  • ANTI-RNA VIRUS DRUG AND APPLICATION THEREOF
    Publication number: 20230097553
    Abstract: An application of a compound represented by formula I or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating RNA virus infection.
    Type: Application
    Filed: February 9, 2021
    Publication date: March 30, 2023
    Inventors: Honglin LI, Ke XU, Zhenjiang ZHAO
  • Applications of novel thiazole derivative in treating virus infection
    Patent number: 11590109
    Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 28, 2023
    Inventors: Ke Xu, Honglin Li, Yufang Xu, Zhenjiang Zhao, Lili Zhu, Wenlin Song, Yi Tong
  • Applications of novel thiazole derivative in treating inflammatory bowel diseases
    Patent number: 11534427
    Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: December 27, 2022
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Honglin Li, Zhenjiang Zhao, Rui Wang, Yufang Xu, Wanqi Wang, Yingfang Yang
  • Saponin compound targeting PD-1 and application thereof
    Patent number: 11464795
    Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
    Type: Grant
    Filed: July 12, 2018
    Date of Patent: October 11, 2022
    Assignees: East China University Of Science And Technology, Yunnan University, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Honglin Li, Weilie Xiao, Lili Zhu, Lina Quan, Qiao Li, Yanyan Diao, Zhenjiang Zhao, Hualiang Jiang
  • Use of pteridinone derivative serving as EGFR inhibitor
    Patent number: 11306095
    Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: April 19, 2022
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Honglin Li, Yufang Xu, Zhenjiang Zhao, Wei Zhou, Yuqiong Xu, Deheng Sun, Xia Wang, Zhuo Chen
  • ANTIHYPERTENSIVE POLYOL COMPOUND AND DERIVATIVE THEREOF
    Publication number: 20220098134
    Abstract: The present invention provides a compound as represented by formula I, or a pharmaceutically acceptable salt or ester, a prodrug, an optical isomer, a stereoisomer, or a solvate thereof. The compound provided by the present invention can be used for preparing drugs for preventing or treating hypertension, or hypertension-related diseases, or pulmonary hypertension, or pulmonary hypertension-related diseases. The compound provided by the present invention has a different mechanism from existing drugs for treating hypertension and pulmonary hypertension, thereby laying a new material foundation for the development of drugs for treating hypertension and pulmonary hypertension.
    Type: Application
    Filed: June 12, 2020
    Publication date: March 31, 2022
    Inventors: Honglin LI, Zhenjiang ZHAO, Rui WANG, Yinchu SHEN, Jianjun FU, Yufang XU, Xuhong QIAN, Qian JIAO, Shiliang LI
  • SELECTIVE JAK2 INHIBITOR AND APPLICATION THEREOF
    Publication number: 20210179598
    Abstract: Provided is a selective JAK2 inhibitor and application thereof. In particular, it relates to the compound of the following Formula (I), and the use of the compound in the treatment of JAK2-mediated related diseases and in the preparation of the medicament for treating JAK2-mediated related diseases.
    Type: Application
    Filed: April 12, 2019
    Publication date: June 17, 2021
    Applicant: East China University of Science and Technology
    Inventors: Honglin LI, Yufang XU, Zhenjiang ZHAO, Lili ZHU
  • QUINAZOLINE COMPOUND SERVING AS EGFR TRIPLE MUTATION INHIBITOR AND APPLICATIONS THEREOF
    Publication number: 20210155604
    Abstract: Related to a quinazoline compound serving as an EFGR triple mutation inhibitor and applications thereof. Specifically, disclosed are a compound as represented by the following formula (I), a pharmaceutical composition comprising the compound of formula (I), and applications of the compound in treating a related disease mediated by EGFR and in a medicament for treating the related disease mediated by EGFR.
    Type: Application
    Filed: April 12, 2019
    Publication date: May 27, 2021
    Inventors: Honglin LI, Jian DING, Yufang XU, Hua XIE, Qiannan LI, Tao ZHANG, Zhenjiang ZHAO
  • Thiazole derivative and applications
    Patent number: 10919869
    Abstract: A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: February 16, 2021
    Assignee: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Honglin Li, Yufang Xu, Rui Wang, Zhenjiang Zhao, Wenlin Song, Liuxin Xu
  • SAPONIN COMPOUND TARGETING PD-1 AND APPLICATION THEREOF
    Publication number: 20200163983
    Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 28, 2020
    Inventors: Honglin LI, Weilie XIAO, Lili ZHU, Lina QUAN, Qiao LI, Yanyan DIAO, Zhenjiang ZHAO, Hualiang JIANG
  • Six-membered ring benzo derivatives as DPP-4 inhibitor and use thereof
    Patent number: 10479798
    Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 19, 2019
    Assignees: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Honglin Li, Hualiang Jiang, Yufang Xu, Jia Li, Zhenjiang Zhao, Jingya Li, Hongling Xu, Shiliang Li
  • APPLICATIONS OF NOVEL THIAZOLE DERIVATIVE IN TREATING INFLAMMATORY BOWEL DISEASES
    Publication number: 20190290620
    Abstract: The present invention relates to applications of a novel thiazole derivative in treating ulcerative colitis and in the preparation of drugs for treating ulcerative colitis.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 26, 2019
    Inventors: Honglin LI, Zhenjiang ZHAO, Rui WANG, Yufang XU, Wanqi WANG, Yingfang YANG
  • THIAZOLE DERIVATIVE AND APPLICATIONS
    Publication number: 20190292162
    Abstract: A thiazole derivative serving as a DHODH inhibitor, and applications thereof. The present invention specifically relates to a compound represented by formula I, a pharmaceutical composition containing the compound represented by formula (I), and applications of the compound in the preparation of drugs for treating diseases mediated by the DHODH or drugs for inhibiting the DHODH.
    Type: Application
    Filed: May 17, 2017
    Publication date: September 26, 2019
    Inventors: Honglin LI, Yufang XU, Rui WANG, Zhenjiang ZHAO, Wenlin SONG, Liuxin XU
  • APPLICATIONS OF NOVEL THIAZOLE DERIVATIVE IN TREATING VIRUS INFECTION
    Publication number: 20190134008
    Abstract: Provided are applications of a thiazole derivative in treating virus infection and in the preparation of drugs for treating virus infection.
    Type: Application
    Filed: June 2, 2017
    Publication date: May 9, 2019
    Inventors: Ke XU, Honglin LI, Yufang XU, Zhenjiang ZHAO, Lili ZHU, Wenlin SONG, Yi TONG
  • System and method for mobile network function virtualization
    Patent number: 10033595
    Abstract: In one embodiment, a method for mobile network function virtualization (MNFV) includes creating an evolved packet core (EPC) cluster and associating a sub-network with the EPC cluster. The method also includes booting a virtual machine (VM) and attaching the VM to the EPC.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: July 24, 2018
    Assignee: Futurewei Technologies, Inc.
    Inventors: Mehdi Sif, Prakash Ramchandran, Hongbo Tian, Houxiao Han, Honglin Li, Mark X. Huang, Farhad Sunavala, Galen Kim Davis
  • USE OF PTERIDINONE DERIVATIVE SERVING AS EGFR INHIBITOR
    Publication number: 20180148454
    Abstract: The present invention relates to a pteridinone derivative serving as an EGFR inhibitor and use thereof. Specifically, the present invention relates to a compound represented by the following formula I, pharmaceutical composition comprising the compound of the following formula I, and use of the compound in preparation of drugs for treating EGFR-mediated diseases or inhibiting EGFR.
    Type: Application
    Filed: May 30, 2016
    Publication date: May 31, 2018
    Inventors: Honglin LI, Yufang XU, Zhenjiang ZHAO, Wei ZHOU, Yuqiong XU, Deheng SUN, Xia WANG, Zhuo CHEN
  • SIX-MEMBERED RING BENZO DERIVATIVES AS DPP-4 INHIBITOR AND USE THEREOF
    Publication number: 20170313715
    Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.
    Type: Application
    Filed: October 30, 2015
    Publication date: November 2, 2017
    Inventors: Honglin LI, Hualiang JIANG, Yufang XU, Jia LI, Zhenjiang ZHAO, Jingya LI, Hongling XU, Shiliang LI
  • Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
    Patent number: 9670213
    Abstract: Provided are a pteridine ketone derivative used as an EGFR, BLK, and FLT3 inhibitor and applications thereof. Specifically, provided are a compound of the following formula I, a pharmaceutical composition containing the compound of the formula I, and use of compound in preparing medicine for treating diseases mediated by EGFR, BLK, or FLT3 or inhibiting EGFR, BLK, and FLT3.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: June 6, 2017
    Assignee: East China University of Science and Technology
    Inventors: Honglin Li, Yufang Xu, Zhenjiang Zhao, Xiaofeng Liu, Wei Zhou, Fang Bai, Mengzhu Xue, Lei Zhang, Youli Zhang